Details for New Drug Application (NDA): 022071
✉ Email this page to a colleague
NDA 022071 describes LAMISIL, which is a drug marketed by Karo Hlthcare and Novartis and is included in eight NDAs. It is available from four suppliers. Additional details are available on the LAMISIL profile page.
The generic ingredient in LAMISIL is terbinafine. There are twenty-seven drug master file entries for this compound. Additional details are available on the terbinafine profile page.
The generic ingredient in LAMISIL is terbinafine. There are twenty-seven drug master file entries for this compound. Additional details are available on the terbinafine profile page.
Summary for 022071
| Tradename: | LAMISIL |
| Applicant: | Novartis |
| Ingredient: | terbinafine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULE;ORAL | Strength | EQ 125MG BASE/PACKET | ||||
| Approval Date: | Sep 28, 2007 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULE;ORAL | Strength | EQ 187.5MG BASE/PACKET | ||||
| Approval Date: | Sep 28, 2007 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
